As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.

The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.

The first podcast in this three-part series introduces the topic of paediatric tuberculosis (TB) and the concept of latent TB infection (L TBI). Statistics on the risk of progression from LTBI to active TB, as well as the risk of severe TB disease, dissemination, and death in children versus adults are shared.

In this episode, Helena and Isabel are joined by Patrick Short, CEO, Sano Genetics, to discuss the challenges and opportunities facing genetic medicine.

Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes

The latest issue of EMJ Oncology is out now featuring engaging content, including a review article examining colorectal cancer during pregnancy and an analysis of optimal immunohistochemical cut-off markers in breast cancer.